Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Auxilium Pharmaceuticals Inc. (UNKNOWN:AUXL.DL) popped 10% today after its quarterly results topped Wall Street expectations.
So what: The stock has slumped over the past year on lackluster revenues, but today's wide Q2 beat -- adjusted EPS of $0.22 topped Wall Street by $0.17 on top-line growth of 29% -- suggests that growth is back on track. While U.S. Testim revenues continued to slump, a spike in U.S. XIAFLEX revenues and the addition of products from newly acquired Actient more than offset the decline, giving analysts plenty of good vibes over Auxilium's product portfolio going forward.
Now what: Management now sees full-year revenue of $363 million-$405 million, versus its prior view of $360 million-$415 million and the average analyst estimate of $372.7 million.
"For the remainder of 2013 and beyond, we will continue to focus on delivering excellence in execution with a new commercial structure and a broader and more diversified product portfolio," said CEO Adrian Adams.
More important, with the stock still off more than 20% from its 52-week highs, there might be plenty of upside left to buy into that bullishness.